- Publication Number: LB-21
- Session: Late-Breaking Poster Session
- Session Date and Time: October 23, 2017 from 8:00 AM to 5:30 PM
- Authors: Christine I. Wooddell, et al.
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it will present preclinical data on ARO-AAT, a second generation investigational medicine for the treatment of alpha-1 liver disease that uses Arrowhead's TRiM TM technology, at The Liver Meeting ® 2017, the Annual Meeting of the American Association for the Study of Liver Disease (AASLD) being held on October 20-24, 2017, in Washington, DC. Poster Presentation: Subcutaneous delivery of a RNA interference (RNAi) therapeutic candidate for alpha-1 antitrypsin deficiency (AATD)-related liver disease produces deep and prolonged knockdown of plasma AAT